MaxCyte

MXCT · NASDAQ

$1.43+$0.13 (+10.00%)TodayMarket closed · Oct 20, 7:58 PM ET

Prev close $1.30

MXCT analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 6 analysts

Average $4.19 (+193.0% upside)

Low: $2.45
Now: $1.43
High: $5.25

Upgrades and downgrades

The latest rating actions, newest first

MXCT analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Craig-Hallum	Mar 25, 2026	Maintains	Buy	$7.00 → $5.00	54%

The case for and against

Updated Oct 23, 2024

Bull case

MaxCyte Inc. is positioned favorably in the growing Cell and Gene Therapy (CGT) industry, with ongoing innovations in non-viral delivery systems highlighting its relevance and potential within the sector. The company demonstrated resilience, as Cell Therapy revenue exceeded expectations by approximately $0.4 million, indicating robust demand for its proprietary Flow Electroporation platform. Furthermore, the maintained revenue guidance of $6 million underscores MaxCyte's stable financial outlook despite broader market competitiveness.

Bear case

MaxCyte Inc. has revised its revenue expectations, anticipating flat to only modest growth of 5% year-over-year for FY24, following a significant 32% decline in core revenue for FY23, with consumable sales down by 42%. The company reported a preliminary revenue miss for Q3 2023 and has lowered its overall revenue guidance for FY23 to $34 million, indicating persistent operational challenges amplified by macroeconomic pressures. Additionally, a reliance on capital-intensive cell and gene therapy (CGT) markets, along with a history of sustained financial losses, raises concerns about the company's short-term viability and long-term growth prospects.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.